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Abstract
Triple-negative breast cancers have a poor prognosis and are not amenable to endocrine- or HER2-targeted thera-
pies. The prevailing view is that targeting the insulin-like growth factor (IGF) signal transduction pathway will not be
beneficial for triple-negative breast cancers because their growth is not IGF-responsive. The present study investi-
gates the importance of IGFs in the proliferation and survival of triple-negative breast cancer cells. Estrogen and
progesterone receptors, HER2, type I IGF, and insulin receptors were measured by Western transfer analysis.
The effects of IGF-1 on proliferation were assessed by DNA quantitation and on cell survival by poly (ADP-ribose)
polymerase cleavage. The effect of IGF-1 on phosphorylation of the IGF receptors, Akt and mitogen-activated pro-
tein kinase, wasmeasured byWestern transfer analysis. Seven cell lines were identified as models of triple-negative
breast cancer and shown to express IGF receptors at levels similar to those present in estrogen-responsive cell lines
known to respond to IGFs. IGF-1 increased the proliferation and cell survival of all triple-negative cell lines. Prolifer-
ation was attenuated after reduction of type I IGF receptor expression. Cells that express higher levels of receptor
were more sensitive to subnanomolar IGF-1 concentrations, but the magnitude of the effects was not correlated
simply with the absolute amount or phosphorylation of the IGF receptors, Akt or mitogen-activated protein kinase.
These results show that IGFs stimulate cell proliferation and promote cell survival in triple-negative breast cancer
cells and warrant investigation of the IGF signal transduction pathway as a therapeutic target for the treatment of
triple-negative breast cancer.
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Introduction
Breast cancer is the most common female cancer in the western world.
Despite improvements in early diagnosis and in clinical management,
breast cancer kills more than 520,000 people worldwide each year.
Approximately 15% of breast cancers are classified as triple-negative
because they do not express estrogen receptor, progesterone receptor,
or HER2 [1,2]. There is considerable overlap between triple-negative
tumors, basal-like tumors, and tumors, which expresses cytokeratins
5 and 6 [3]. Triple-negative tumors are more prevalent in younger [4]
and in black women [4,5]. They account for 27% of breast cancer
cases diagnosed in premenopausal African Americans, 25% in younger
black British women, and 27% in all indigenous Africans [6,7]. Basal-
like breast cancers have a tendency toward visceral, versus bone, metas-
tasis [7,8]. They present at a similar clinical stage to other subtypes but
have a worse prognosis [8]. BRCA1, but not BRCA2-associated, breast
tumors are predominantly triple-negative or basal-like [9,10].
Women with triple-negative tumors have limited therapeutic op-
tions. They are unlikely to benefit from endocrine therapies that exploit
the dependence of tumor cells on estrogens or from trastuzumab, the
anti-HER2 antibody, which targets the dependence of tumor cells on
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signaling through the HER2 oncogene. They are treated with conven-
tional chemotherapies, which have limited efficacy and unpleasant
adverse side effect profiles [1,11,12]. There is an urgent need for non-
cytotoxic, targeted therapies that could prolong the lives of women with
triple-negative breast cancer.
Insulin-like growth factors (IGFs) of which there are three ligands,
namely, IGF-1, IGF-2, and insulin, transmit their signals through
two paralagous receptor proteins located in the plasma membrane:
the type I IGF receptor and the insulin receptor (IGF receptors).
The type I IGF and insulin receptors are heterotetrameric proteins
with intrinsic phosphotyrosine activity. IGF-1 and IGF-2 have higher
affinities for the type I receptor, whereas insulin has a relatively higher
affinity for the insulin receptor. The ligands interact with extracellular
domains of the receptors and induce phosphorylation of and confor-
mational changes in the receptors, which, in turn, facilitate recruitment
and phosphorylation of the intracellular adaptor proteins. The signaling
cascades initiated lead to activation of proteins such asmitogen-activated
protein kinase (MAPK) andAkt and ultimately to increased cell survival,
proliferation, and migration [13].
The IGF system is involved in tumorigenesis and the proliferation,
survival, and migration of tumor cells. High circulating IGF-1 con-
centrations and low blood IGF binding protein concentrations are a
risk factor for several types of cancer including breast cancer [14–16].
Components of the IGF signal transduction pathway are expressed
widely and often at high levels in cancer cells [17].
IGF antagonists have been developed, several of which have entered
clinical trials [18–22]. These include humanized antibodies to the
type I IGF receptor and tyrosine kinase inhibitors. In breast cancer,
the antibody figitumumab is being tested in combination with exemes-
tane and docetaxol, the tyrosine kinase inhibitor AMG479 in combina-
tion with exemestane and fulvestrant, and the antibody cixutumumab
with temsirolimus and lapatinib or capecitabine in HER2-positive
breast cancers.
The emphasis of the breast cancer trials has been to try to augment
the effect of hormone therapy, the rationale being based on labora-
tory studies that show that there are synergistic effects of estrogens
and IGFs on the proliferation of estrogen-responsive breast cancer
cells [23–27]. The presence of a functional IGF signal transduction
pathway in estrogen-unresponsive breast cells has received little atten-
tion and is controversial. One study reported that estrogen-unresponsive
cells show proliferative response to IGFs [23], but most studies con-
clude that estrogen unresponsive cells show no mitogenic response to
IGFs [28–31].
In the present study, we reevaluate the importance of IGF signal trans-
duction in triple-negative breast cancer cells. We show that all triple-
negative breast cancer cells tested express IGFreceptors, that components
of the IGF signal transduction pathway are phosphorylated in response to
IGF-1, and that IGF-1 stimulates cell proliferation and cell survival. This
preclinical study provides a rationale for the future clinical investigation
of the therapeutic efficacy of type I IGF receptor inhibitors in the treat-
ment of triple-negative breast cancer.
Materials and Methods
Cell Culture
Breast cell lines established from malignant breast epithelial cells:
BT-474, MCF-7, T-47D, ZR-75, EFF-3, EFM-19, MDA-MB-435s,
Hs 578T, BT-20, and SK-BR-3 cells were cultured routinely in Dul-
becco modified Eagle medium (DMEM), supplemented with 10%
fetal calf serum (FCS) and 1 μg/ml insulin. MDA-MB-231 cells were
cultured in DMEM, 5% FCS, and 1 μg/ml insulin; MDA-MB-468
cells were cultured in DMEM/Hams F12 nutrient, 10% FCS, and
1 μg/ml insulin; and BT-549 cells were cultured in RPMI, 10%
FCS, and 1 μg/ml insulin. HBL-100 breast epithelial cells that were
isolated from human milk but have become transformed during
culture were cultured in DMEM, 10% FCS, and 1 μg/ml insulin.
Spontaneously immortalized MCF-10A breast epithelial cells isolated
from normal breast tissue were cultured in DMEM/Hams F12 nu-
trient mix supplemented with 5% horse serum, 0.5 μg/ml hydrocor-
tisone, 100 ng/ml cholera toxin, 10 μg/ml insulin, and 20 ng/ml
EGF. Cells were obtained from the American Type Culture Collec-
tion (Manassas, VA). It was suggested that the MDA-MB-435s cell
line might be of melanoma origin, but it has been validated as a
breast cancer cell line [32,33]. Nonimmortalized human mammary
epithelial cells (HUMECs) were cultured in the specialist medium
provided by the supplier (Invitrogen, Paisley, United Kingdom).
Western Transfer Analysis
Cells were grown in routine culture media and lysed in RIPA lysis
buffer, and the protein concentration was measured with a bicinchonic
acid assay (Thermo Scientific, Loughborough, UK). Equal amounts of
protein were separated by polyacrylamide gel electrophoresis and trans-
ferred to 0.45-μm nitrocellulose membrane [34,35]. Membranes were
incubatedwith specific antibodies: estrogen receptorα (05-820;Upstate
Biotechnology, Inc, Watford, United Kingdom); HER2 (NCL-CBE1;
Novocastra, Milton Keynes, United Kingdom); type I IGF receptor
(#3027), phospho-IGF receptors (#3024) phospho-ERK1/2 (#9102),
and phospho-Akt (#4060) (Cell Signaling Technologies, Hitchin,
United Kingdom); insulin receptor (sc-81466) and GAPDH (Santa Cruz
Biotechnology, Heidelberg, Germany);α-tubulin (Sigma, Poole, United
Kingdom); and poly (ADP-ribose) polymerase (PARP, 556494; BD
Biosciences, Oxford, United Kingdom) using the concentrations and
conditions recommended by the supplier. Phospho-specific anti-
bodies that detect activated type I IGF receptor autophosphorylated
on tyrosines 1135 and 1136 interact also with activated insulin receptor
autophosphorylated on tyrosines 1150 and 1151. The phospho-MAPK
antibody detects Erk1 when it is phosphorylated on Thr 202 and or
Tyr 204 and Erk2 when it is phosphorylated on Thr 185 and or
Tyr 187. The phospho-Akt antibody detects Akt when it is phosphor-
ylated on Ser 473. Proteins were visualized by incubating the filters with
horseradish peroxidase–conjugated secondary antibody followed by
enhanced chemiluminescence with SuperSignal West Dura Substrate
(Thermo Scientific) and exposure to an x-ray film. The intensity of
the signal was quantified by densitometric analysis using LabWorks
4.0 software (UVP, Inc, Cambridge, United Kingdom).
Cell Proliferation
Cells were seeded into 16-mm-diameter wells at a density of 4000
cells per well (MDA-MB-231, MDA-MB-435s), 7000 cells per well
(MDA-MB-468, Hs 578T), or 10,000 cells per well (BT-549) allowed
to attach for 24 or 40 hours and withdrawn from the effects of untreated
serum for 2 to 3 days by replacing the medium twice daily [23,24,36]
with growth factor–depleted medium comprising phenol red–free
DMEM supplemented with 5% or 10% charcoal-treated calf serum
[37]. Cells were incubated subsequently in various concentrations of
IGF-1 for 3 to 12 days. Medium was changed daily. Cell growth was
determined by measuring the amount of DNA in each well using Pico-
Green dsDNA Quantitation Reagent (Invitrogen) [38].
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Knockdown of Type I IGF Receptor
Cells were seeded into 16-mm-diameter wells at a density of 5000
cells per well (MDA-MB-231) or 7000 cells per well (Hs 578T) allowed
to attach for 24 hours and grown for 4 days in routine maintenance me-
dium. The medium was changed daily. Cells were washed twice with
PBS, maintenance medium was replenished, and cells were transfected
with 12.5 μg/ml empty vector or shRNA plasmid pKD-IGF-IR-v2
(Upstate Biotechnology) in the presence of a 3:1 ratio of FuGENE
HD transfection reagent (Roche, Burgess Hill, United Kingdom) and
incubated for 24 hours at 37°C as described previously [35]. Cells were
then washed twice with PBS and incubated in withdrawal medium
in the absence and presence of 50 ng/ml IGF-1 for 3 days at 37°C. Cells
were lysed, and aliquots of protein lysate were analyzed by Western
transfer for expression of the type I IGF receptor.
To test the effects of the knockdown on cell proliferation, cells
were seeded into 16-mm-diameter wells at a density of 5000 cells
per well (MDA-MB-231) or 7000 cells per well (Hs 578T), allowed
to attach for 46 hours, washed with PBS, and transfected with the
plasmids at a 3:1 ratio of FuGENE HD to DNA. After 18 to 24 hours,
the cells were washed twice with PBS, and the medium was replaced
with withdrawal medium in the absence and presence of IGF-1 for 3 to
6 days. After 3 days of culture, the cells were retransfected with the
plasmids. The medium was changed daily. Cell growth was determined
by measuring the amount of DNA in each well using PicoGreen
dsDNA Quantitation Reagent (Invitrogen) [38].
Cell Survival
Cells were seeded into 35-mm-diameter wells at a density of 400,000
cells per well and allowed to attach for 24 hours. Cells were then with-
drawn for 2 days and subsequently pretreated with various concentra-
tions of IGF-1 for 1 hour before incubation with 1 μM staurosporine
for different lengths of time followed by lysis in RIPA buffer.
Programmed cell death was evaluated by the extent of PARP cleavage
determined by Western transfer analysis with a PARP antibody specific
to both cleaved and uncleaved PARP as described previously.
IGF-I–Stimulated Protein Phosphorylation
Cells were seeded into 35-mm-diameter wells in routine culture
medium and allowed to attach for 24 hours. Cells were then with-
drawn from the stimulating effects of untreated serum for 2 days.
The medium was changed twice daily with phenol red–free DMEM
supplemented with 10% dextran-coated charcoal-treated calf serum
[37]. Cells were then incubated for 2 hours in serum-free medium
and subsequently in various concentrations of IGF-1 for 15 minutes
and lysed in RIPA buffer. Phosphorylated proteins were detected by
Western transfer analysis as described above.
Statistics
Experiments were replicated at least three times. For the results
shown in Figures 1–5, a representative example is shown. For the results
shown in Figures 3B, 6, and 7, data were normalized and expressed as a
percentage of the maximum IGF-stimulated effect. Results from inde-
pendent experiments are expressed as means ± SEM. Differences
between groups were tested by analysis of variance, paired or unpaired
t test; P < .05 was considered statistically significant.
Results
Receptor Expression
Expression of the estrogen receptor, progesterone receptor, andHER2
was assessed in 14 transformed and 2 untransformed human breast
epithelial cell lines (Figure 1). There was variable but generally high
expression of estrogen receptor in the six known estrogen-responsive cell
lines, BT-474, MCF-7, T-47D, ZR-75, EFF-3, and EFM-19 [39–41].
EFM-19 cells express the highest and BT-474 cells the lowest levels
(t test, P < .05). No estrogen receptor was detected in the other cell lines
even after prolonged exposure of the filters to the x-ray film.
Expression of the progesterone receptor was restricted also to the
estrogen-responsive cell lines [42]. Expression was relatively high in
MCF-7, T-47D, and EFM-19 cells and was lower in BT-474, ZR-75,
and EFF-3 cells (t test, P < .05). HER2 was expressed at highest levels
in SK-BR-3 and BT-474 cells (t test, P < .05), in which HER2 is am-
plified [39], in MCF-7, T-47D, EFF-3, and EFM-19 breast cancer
cells and in MCF-10A and HUMEC untransformed breast cells.
These results show that seven of the cell lines, BT-20, MDA-MB-
231, MDA-MB-468, MDA-MB-435s, Hs 578T, BT-549, and HBL-
100, do not express estrogen and progesterone receptors or HER2
and are potential models of triple-negative breast cancer.
To evaluate if IGF signal transduction pathways might be impor-
tant in triple-negative breast cancer cells, the expression of the type I
IGF and insulin receptors was compared with expression in estrogen-
responsive cells that are known to respond to IGFs (Figure 1B). All
cell lines expressed the type I IGF receptor. Among the estrogen-
responsive cell lines, MCF-7 and EFM-19 cells express the highest
and EFF-3 the lowest levels (t test, P < .05). Of the triple-negative
breast cancer cell lines, BT-20, MDA-MB-231, MDA-MB-468,
MDA-MB-435s, and HBL-100 express high levels similar to those in
MCF-7 and EFM-19 cells. The triple-negative cell lines that express
lower levels of the type I IGF receptor still express more receptor than
EFF-3 cells (t test, P < .05). The SK-BR-3 and untransformed MCF-
10A cell lines express moderate amounts of the receptor, whereas
HUMEC normal breast epithelial cells express higher levels.
The insulin receptor was detected in all estrogen-responsive and
triple-negative cell lines. The highest expression was in BT-474, T-
47D, and SK-BR-3 (t test, P < .05), whereas it was lower in MDA-
MB-468, MDA-MB-435s, and BT-549 cells. The ratio of type I IGF
to insulin receptors varied across the 16 cell lines. MCF-7, EFM-19,
MDA-MB-231, MDA-MB-435s, and BT-549 cells expressed rela-
tively higher levels of the type I IGF receptor, whereas BT-474,
EFF-3, and SK-BR-3 cells expressed relatively higher levels of the insu-
lin receptor. T-47D cells expressed high levels of both receptors and
Hs 578T cells expressed low levels of both receptors.
These results show considerable variation in expression of the IGF
receptors but overall expression is similar in triple-negative and estrogen-
responsive cells. The relatively high expression of the IGF receptors in
triple-negative breast cancer cells suggests that the IGF signal transduc-
tion pathway may be important in controlling cell proliferation and cell
survival in this subtype of breast cancer.
Effect of IGF-1 on Triple-Negative Breast Cancer Cell
Proliferation and Survival
Although screens with small-molecule inhibitors of the type I IGF
receptor have reported efficacy in triple-negative breast cancer cell
lines [21], and we have reported previously that IGF-1 stimulates
the proliferation of triple-negative MDA-MB-231 cells [23], the
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current view is that IGFs are not mitogenic for triple-negative breast
cancer cells [28–31]. After demonstration of significant expression of
IGF receptors by triple-negative breast cancer cell lines, we investi-
gated the effect of IGF-1 on their growth. Growth rates of MDA-
MB-231, MDA-MB-435s, Hs 578T, and BT-549 cells were similar
in the absence of IGF-1 (Figure 2). IGF-1 stimulated the proliferation
of these four cell lines. MDA-MB-231 cells were the most responsive
to IGF-1 treatment and cell numbers were increased eight-fold after
9 days of treatment. MDA-MB-435s and Hs 578T showed inter-
mediate responses with cell numbers increased approximately four-
fold, whereas BT-549 cells were less responsive and were increased
two-fold.
MDA-MB-468 cell proliferation was stimulated by IGF-1, but the
cells were rounded and attached poorly to standard tissue culture
plastic. Corning CellBIND plates (Fisher Scientific, Loughborough,
United Kingdom) improved cell attachment. MDA-MB-468 cells
Figure 1. Expression of steroid and growth hormone receptors in cultured breast cells. BT-474,MCF-7, T-47D, ZR-75, EFF-3, EFM-19, BT-20,
MDA-MB-231 (MDA-231), MDA-MB-468 (MDA-468), MDA-MB-435s (MDA-435s), Hs 578T, BT-549, HBL-100, SK-BR-3, MCF-10A, and
HUMEC (HUM) cells were grown to 70% confluence in routine culture medium and lysed, and 20 μg of protein was electrophoresed on
polyacrylamide gels and transferred to nitrocellulose as described in theMaterials andMethods. Membranes were incubated with estrogen
receptor (67 kDa), progesterone receptor (118 kDa), HER2 (185 kDa) (A), type I IGF receptor (95 kDa), or insulin receptor (95 kDa) (B) anti-
bodies and developed by enhanced chemiluminescence as described in the Materials and Methods. Representative Western transfer
images are shown on the left-hand side of the figure. The membranes were incubated secondly with a GAPDH antibody (data not shown),
which confirmed equal loading and transfer. The analysis was repeated at least twice on four or more individual samples prepared from
MCF-7, T-47D, ZR-75, EFF-3, EFM-19, MDA-MB-231, Hs 578T, BT-20, HBL-100, and SK-BR-3 breast epithelial cells and on three individual
samples prepared from BT-474, MDA-MB-435s, MDA-MB-468, BT-549, MCF-10A, and HUMEC cells. The amount of each protein was de-
termined by densitometric scanning of x-ray films followed by analysis with LabWorks 4.0 software and correcting for GAPDH as described
in the Materials and Methods. The amount of each protein was expressed as the percentage of the amount of protein in the cell line that
expresses the most of that protein and is represented in the histograms shown on the right hand side of the figure. Mean values ± SEM are
shown. The filled columns indicate expression in triple-negative cell lines.
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grewmore slowly in the growth factor–depleted medium than the other
triple-negative breast cancer cells; however, cell numbers were increased
four-fold after 12 days of treatment with IGF-1.
In contrast to most studies, our experiments establish unequivocally
that cell growth of triple-negative breast cancer cells is increased by IGF-1.
The effect of decreasing the expression of the type I IGF receptor on
IGF-1–stimulated cell proliferation was tested. The expression of type I
IGF receptor by MDA-MB-231 and Hs 578T cells was reduced to
barely detectable levels after transfection of the cells with an shRNA
plasmid as described in the Materials and Methods (Figure 3, A and B).
The proliferative response of MDA-MB-231 and Hs 578T cells was
reduced significantly in cells in which endogenous expression of the
type I IGF receptor had been lowered (Figure 3, C and D).
IGFs protect a wide variety of cell types against cell death induced
by insults including ionizing radiation and cytotoxic drugs both of
which are used widely in the treatment of cancer. There have been
Figure 2. Stimulation of proliferation of triple-negative breast cancer cells by IGF-1. MDA-MB-231,MDA-MB-435s, Hs 578T, and BT-549 cells
were plated in 16-mm-diameter tissue culture wells, allowed to attach, withdrawn from the growth stimulatory effects of normal culture
medium, and then cultured for the indicted lengths of time in the absence (○) or presence (•) of 50 ng/ml IGF-1 as described in the Materials
and Methods. MDA-MB-468 cells were plated in Corning CellBIND plates. Cells were lysed, and the DNA content of the wells was mea-
sured. Bars, SEM. Asterisks show times at which there were significantly more cells in the presence of IGF-1 than in its absence.
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no studies of the cell survival effect of IGFs in triple-negative breast
cancer. Programmed cell death through the caspase-dependent path-
way leads to cleavage of PARP from 113 to 89 kDa, thus removing
the DNA binding domain. There was no detectable PARP cleavage
in any of the cell lines after culture in growth factor–depleted medium.
Therefore, to investigate whether IGF-1 promotes cell survival in triple-
negative breast cancer cells, the ability of IGF-1 to inhibit staurosporine-
induced cell death was measured. Staurosporine binds with high affinity
to the ATP binding site of protein kinases, which inhibits their enzy-
matic activity and activates the caspase-dependent apoptotic pathway.
The triple-negative cells responded differently to staurosporine.
Typically, PARP cleavage after the addition of staurosporine was ob-
served first after 4 hours (MDA-MB-231 and HBL-100) but BT-549
cells responded more slowly (Figure 4A). The degree of protection
against staurosporine conferred by IGF-1 varied but was generally
pronounced; the time taken for cleaved PARP to become detectable
increased and the percentage of cleaved PARP at later times decreased
in the presence of IGF-1. Exposure of MDA-MB-468 cells to stauros-
porine for 2 and 4 hours decreased the amount of 113-kDa uncleaved
PARP, and the decrease was attenuated by IGF-1 but cleaved 89-kDa
PARP protein was not detected. This suggests that once cleaved by
caspases, PARP is degraded rapidly in these cells.
The percentage of cleaved PARP was quantified for the six cell
lines in which it was detected (Figure 4B). In Hs 578T cells, the most
staurosporine-sensitive cell line, IGF-1 delayed the appearance of
cleaved PARP by 30 minutes, and there was a 40% reduction in
the amount of cleaved PARP after 2 hours. The delay was longer,
and the reduction was greater in the other cell lines. PARP cleavage
was delayed by 4 hours in MDA-MB-231 and HBL-100 cells and
reduced 20-fold and 10-fold, respectively. It was delayed by 2 hours
in BT-20 and MDA-MB-435s cells, in which it was reduced five- and
three-fold, respectively. There was no cleaved PARP in the presence of
IGF-1 in BT-549 cells.
Clearly, these experiments show that IGF-1 has a significant and, in
some cases, a dramatic protective effect against staurosporine-induced
programmed cell death in triple-negative breast cancer cells. In addi-
tion, they provide evidence that the effect of IGF-1 on cell prolifera-
tion results from increased cell division rather than decreased cell
death because there is no detectable cleaved PARP in any of the cell
lines in the absence of staurosporine.
IGF-1–Stimulated Phosphorylation of IGF Receptors and
Downstream Signal Transduction Proteins
In general, the level of expression of the type I IGF receptor was
related to the response of the cells; for instance, MDA-MB-231 cells
that express high levels of receptor show the greatest effects of IGF-1 on
cell proliferation and survival. However, there were some anomalies;
Hs 578T cells express low levels of type 1 IGF receptor, but both pro-
liferation and survival show large responses to IGF-1. To determine
whether this anomaly could involve significant differences in receptor
phosphorylation or compensation by other components of the signal
transduction pathway, the amount of the phosphorylated IGF receptors
and two key downstream signal transduction molecules Akt andMAPK
was assessed. Akt functions as a cardinal nodal point for transducing
extracellular and intracellular oncogenic signals. MAPK (ERK1/2) is
activated preferentially in response to growth factors and phorbol ester
and regulates cell proliferation and differentiation.
IGF-1 stimulated phosphorylation of the IGF receptors in all seven
triple-negative breast cancer cell lines and in the HER2-positive SK-
BR-3 cell line (Figure 5). There was a good correlation between the
amounts of receptors expressed and the amount of phosphorylated
receptors after treatment with IGF-1. For example BT-20, MDA-
MB-231, and HBL-100 cells express high levels of IGF receptors and
high levels of phosphorylated receptor were detected after IGF-1 treat-
ment, whereas for Hs 578T cells that contain low levels of receptors,
the phosphorylated receptor was visible only after prolonged exposure
of the membrane to an x-ray film.
IGF-1 treatment caused pronounced stimulation of the phosphory-
lation of Akt and of MAPK in the seven triple-negative cell lines and in
SK-BR-3. The amount of total Akt and MAPK did not change. The
increase in the level of phosphorylated MAPK and Akt after IGF-1
treatment did not always reflect the level of phosphorylated IGF
receptor. MDA-MB-231 cells, which have among the highest levels
of phosphorylated receptor, have the lowest level of phosphorylated
Akt, and MDA-MB-468, Hs 578T and, BT-549 cells, which have
low levels of phosphorylated receptor, have relatively high levels of
phosphorylated Akt after IGF-1 stimulation. These apparent discrep-
ancies may be explained in part by the total levels of the effector
Figure 3. Effect of decreased expression of type I IGF receptor on
cell proliferation in MDA-MB-231 and Hs 578T cells. MDA-MB-231
(A) and Hs 578T (B) cells were transfected with shRNA plasmid
pKD-IGF-IR-v2 and then cultured for 3 days in the absence or pres-
ence of 50 ng/ml IGF-1. Cells were lysed, and 20 μg of protein was
electrophoresed on polyacrylamide gels and transferred to nitro-
cellulose. Membranes were incubated with type I IGF receptor
(95 kDa) antibody and developed by enhanced chemiluminescence
as described in theMaterials andMethods. Representative Western
transfer images after exposure to the x-ray film for 30 seconds (A)
and 3 hours (B) are shown. The membranes were incubated sec-
ondly with a GAPDH antibody (data not shown), which confirmed
equal loading and transfer. MDA-MB-231 (C) and Hs 578T (D) cells
were transfected with shRNA plasmid pKD-IGF-IR-v2 and then cul-
tured in the absence or presence of 50 ng/ml IGF-1 as described in
the Materials and Methods. Cells were lysed, and the DNA content
of the wells was measured. Bars, SEM. Asterisks show times at
which there were significantly fewer cells grown in the presence of
50 ng/ml IGF-1 in the wells that contained cells transfected with
pKD-IGF-IR-v2 than in wells that contained cells transfected with the
control plasmid (t test, P < 0.05).
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Figure 4. Protective effect of IGF-1 on programmed cell death in triple-negative breast cancer cells. MDA-MB-231, HBL-100, BT-549,
MDA-MB-468, Hs 578T, BT-20, and MDA-MB-435s cells were cultured and treated with staurosporine in the absence and presence of
50 ng/ml IGF-1 as described in the Materials and Methods. Cells were lysed after various times, and the amount of PARP cleavage was
measured by Western transfer analysis. Representative Western transfer images are shown in A. The positions of cleaved and un-
cleaved PARP proteins are indicated on the right of the images. The amount of each protein was determined by densitometric scanning
of the x-ray films followed by analysis with LabWorks 4.0 software. In B, the amount of cleaved 89-kDa form of PARP protein expressed
as a percentage of total PARP protein is shown in the absence (○) or presence (•) of IGF-1. Bars, SEM. Asterisks show PARP cleavage
that is statistically significantly less in the presence of IGF-1 than in its absence.
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proteins. MDA-MB-231 cells express relatively low levels of Akt,
whereas MDA-MB-468, Hs 578T, and BT-549 cells express relatively
higher levels of Akt. Similarly, the relatively high levels of phosphor-
ylated MAPK detected after IGF-1 treatment, in MDA-MB-468,
MDA-MB-435s, and even higher levels in HBL-100 cells, may be
partly because MAPK expression is relatively high in these cell lines.
Our results suggest that higher concentrations of downstream effec-
tor proteins may, in part, compensate for low receptor concentrations to
allow a triple-negative breast cancer cell with low IGF receptor concen-
trations to respond to IGF-1.
Concentration Dependence of the IGF-1 Effect on the
Phosphorylation of Signaling Proteins, Cell Proliferation,
and Cell Survival
Although IGF-1 stimulates proliferation and provides robust pro-
tection from induction of cell death in cells that express high and low
levels of IGF receptors, the receptor level could influence the sensitivity
to IGF-1, and this could have implications for IGF-targeted therapy.
We therefore investigated the hypothesis that differing levels of receptor
expression and phosphorylation control the sensitivity of the biologic
response to IGF-1.
Figure 5. Phosphorylation of IGF receptors, Akt and MAPK, in response to IGF-1 in triple-negative breast cancer cells. BT-20, MDA-MB-231,
MDA-MB-468, MDA-MB-435s, Hs 578T, BT-549, HBL-100, and SK-BR-3 cells were seeded in routine culture medium, cultured for 2 days in
phenol red–free medium supplemented with charcoal-treated serum, for 2 hours in serum-free medium, and then stimulated with 50 ng/ml
IGF-1 for 15 minutes in the same medium, and protein lysates were prepared. Aliquots of 10 μg of protein were electrophoresed on a
polyacrylamide gel; transferred to nitrocellulose; incubated with phospho-IGF receptor, phospho-Akt, or phospho-ERK1/2 antibodies;
and developed using enhanced chemiluminescence as described in the Materials and Methods. Because we detected exceptionally high
amounts of phosphorylated Akt andMAPK in BT-20 cells and of phosphorylatedMAPK in HBL-100 cells, lower exposures of themembranes
to the x-ray films are shown for these proteins. The membranes were incubated secondly with a tubulin antibody to confirm equal loading
and transfer. The protein samples were analyzed to measure the total level of the proteins and to confirm that the levels do not change
during the experiment. Representative images of the results obtained are shown underneath the panels of the corresponding phosphory-
lated proteins.
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The concentration dependence of IGF-stimulated receptor phosphor-
ylation was measured in MDA-MB-231 cells that express high levels
of the type I IGF and insulin receptors, in MDA-MB-468 cells that
express significant levels of the type I IGF receptor only, and in Hs
578T cells that express low levels of both receptors (Figure 6). In
all three cell lines, the amount of phosphorylated receptor detected
was near-maximal at 25 ng/ml IGF-1 and half-maximal at around
6 ng/ml IGF-1. Attenuation of receptor phosphorylation at high ligand
concentrations was not detected in any cell line. The important dif-
ferences between the cell lines were that de facto the total amount of
phosphorylated receptor present after stimulation with saturating con-
centrations and subsaturating concentrations varied, reflecting the level
of expression of the receptor. Also, the fold increase in the amount of
phosphorylated receptor detected at 0.5 ng/ml IGF-1 and 25 ng/ml
IGF-1 differed. This fold difference was more than 1000-fold for
MDA-MB-231 cells, more than 100-fold for MDA-MB-468 cells,
and approximately 6-fold for Hs 578T cells.
We next investigated the concentration dependence of phosphor-
ylation of Akt and MAPK, proliferation and cell survival in MDA-
MB-231, which express high levels of receptor, and Hs 578T cells,
which express low levels. Both Akt and MAPK were phosphorylated
at lower IGF-1 concentrations in MDA-MB-231 than in Hs 578T
(data not shown). There was a clear proliferative response of both cell
lines to low IGF-1 concentrations, but MDA-MB-231 cells were more
sensitive thanHs 578T cells (Figure 7, A and B). IGF-1 increasedMDA-
MB-231 cell proliferation at 50 pg/ml, whereas an increase in Hs
578T cell number was only significant at concentrations of 2 ng/ml
IGF-1 and higher. The magnitude of the proliferative effect increased
to reach a maximum at 50 ng/ml IGF-1 for MDA-MB-231 cells and
100 ng/ml IGF-1 for Hs 578T cells. The proliferative effect of IGF-1
in MDA-MB-231 cells was attenuated somewhat at concentrations
greater than 50 ng/ml.
For cell survival, there was a clear response of both cells lines to low
IGF-1 concentrations (Figure 7, C andD). A protective effect of IGF-1
was first detected in MDA-MB-231 cells at 50 pg/ml IGF-1. The pro-
tective effect reached a maximum at around 10 ng/ml IGF-1 but was
attenuated at higher concentrations. InHs 578T cells, a protective effect
of IGF-1 was detected at concentrations greater than 500 pg/ml. The
magnitude of the IGF-1 survival effect increased with higher IGF-1
concentrations to reach a maximum around 200 ng/ml IGF-1.
These results show that the growth and survival of triple-negative
breast cancer cells with very different concentrations of type I IGF
receptor is increased by low IGF-1 concentrations. The sensitivity
to IGF-1–stimulated autophosphorylation of the type I IGF receptor
cells is the same for cells that express high and low receptor concen-
trations, but cells that express higher levels of receptor are more sen-
sitive for the activation of downstream signaling molecules and for
the induction of biologic responses.
Discussion
All breast cancer cell lines expressed type I IGF receptor irrespective of
their estrogen receptor status, and there was no association between
type I IGF receptor expression and estrogen responsiveness. This is
unexpected because type I IGF receptor expression is increased by
estrogen in estrogen-responsive breast cancer cells [23,35] and is asso-
ciated with estrogen receptor expression in large series of breast tumors
[43,44]. It is in agreement, however, with early studies that showed by
ligand binding that similar amounts of IGF receptor are expressed on
Figure 6. Stimulation of phosphorylationof IGF receptors by different
concentrations of IGF-1. MDA-MB-231 (A), MDA-MB-468 (B), and Hs
578T (C) cells were withdrawn for 2 days and then incubated in the
presence of the indicated concentrations of IGF-1 for 15 minutes.
Cells were lysed, and phosphorylation of IGF receptors was mea-
sured andquantified asdescribed in theMaterials andMethods. Rep-
resentative images from the membranes after exposure to an x-ray
film for 1 minute (MDA-MB-231), 10 minutes (MDA-MB-468), and
5 hours (Hs 578T) are shown as inserts. The amount of phosphory-
lated receptorwas determined by densitometric scanningof the x-ray
films followed by analysis with LabWorks 4.0 software. Bars, SEM.
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the cell surfaces of estrogen-unresponsive MDA-MB-231 cells and
estrogen-responsive MCF-7 cells treated with estrogen [23]. Others
studies have measured type I IGF receptor in triple-negative breast
cancer cell lines notably in MDA-MB-231 cells [28,29,45] but have
not compared type I IGF receptor expression in the different triple-
negative breast cancer cell lines described in the present study.
IGF receptor phosphorylation was stimulated by IGF-1 in all triple-
negative cell lines tested. Few studies have measured phosphorylated
IGF receptor in breast tumors. The study of Law et al. [46] is of interest
because it suggests that the level of phosphorylated receptor is indicative
of poor prognosis, whereas previous studies suggested that total type I
IGF receptor levels were of no prognostic value [47] or were indicative
of good prognosis [43].
We demonstrate that the IGF signal transduction pathway is active
in triple-negative breast cancer cells and that its activation increases
cell proliferation and promotes cell survival in all the triple-negative
breast cell lines tested. Further, decreased type I IGF receptor expres-
sion reduced cellular proliferation of triple-negative cells. Supportive of
the clinical relevance of our findings, IGF inhibitors were effective in a
mouse model of basal cell mammary cancer [48], an IGF gene signature
has been reported in triple-negative breast tumors [49], and Law et al.
[46] found that phosphorylated IGF receptors were indicative of poor
prognosis in all breast cancer types.
The effects of IGFs on the proliferation of estrogen-unresponsive,
triple-negative breast cancer cells are controversial. Our early study re-
ported that the growth of MDA-MB-231 cells is increased by IGF-1
[23], but subsequent studies have reported no effect in MDA-MB-
231 [28], MDA-MB-468 [29,30], MDA-MB-435A [30], and Hs
578T cells [31]. The reasons for the discrepancies are not known,
but the culture conditions used for the proliferation assays may be crit-
ical. It may be important that cells are withdrawn from the stimulatory
effect of IGF-1 and high concentrations of insulin present in most rou-
tine cell culture medium. It may be important that cells are not cultured
in a minimal, serum-free medium in which cells may be refractory to
stimuli. Other explanations for the different results obtained in the
present study and those reported by other workers are the different den-
sities of the cells and the frequency of medium change, which may
affect the impact of molecules released by the cells themselves [31]. It
Figure 7. Stimulation of cell proliferation and cell survival by different concentrations of IGF-1. MDA-MB-231 (A) and Hs 578T (B) cells
were withdrawn from growth stimuli and cultured in the presence of the indicated concentrations of IGF-1. Cells were lysed, and the
DNA content of the wells was measured as described in the Materials and Methods. MDA-MB-231 (C) and Hs 578T (D) cells were
treated with staurosporine in the absence or presence of the indicated concentrations of IGF-1. Cells were lysed, and the percentage
of PARP cleavage was determined as described in the Materials and Methods. Bars, SEM. Asterisks indicate the lowest concentration of
IGF-1 at which a significant effect of IGF-1 was detected.
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may also be relevant that most studies have tested the effects of IGFs
over relatively short times, whereas experiments were more prolonged
in the present study. After 3 days of IGF-1 treatment, the discernible
increase in cell number was either small or not significant. Although the
magnitude of the effect varied, cell growth was stimulated by IGF-1 in
all five triple-negative breast cancer cell lines studied. Interestingly,
whereas the greatest effect on proliferation occurred in a cell line that
expresses high concentrations of IGF receptors, one of the highest fold
increases in cell number stimulated by IGF-1 occurred in Hs 578T
cells, which contain relatively low concentrations of IGF receptors
and low IGF-1 stimulation of IGF receptor phosphorylation.
The protective effects of IGF-1 against induction of triple-negative
breast cancer cell death reported in this study are dramatic. The effect of
IGFs on cell survival of triple-negative breast cancer cells has not been
reported. Similarly to cell proliferation, the ability of IGF-1 to inhibit
induction of cell death was not affected markedly by the amount of
expression or phosphorylation of the IGF receptors.
Our results suggest that, in addition to the concentrations of the
IGF receptors, concentrations of downstream effector proteins may
contribute to the ability of triple-negative breast cancer cells to re-
spond to IGFs. The expression levels of adaptor proteins could con-
tribute also to IGF responsiveness especially in cells such as Hs 578T
that have relatively low concentrations of IGF receptors. We have
shown recently that both Hs 578T and HBL-100 cells express rela-
tively high levels of the major IGF receptor adaptor protein, insulin
receptor substrate 1 (IRS-1) compared with MDA-MB-231 cells
[35]. One explanation for the robust response of Hs 578T cells
and HBL-100 cells to IGF-1 is that they express high levels of
IRS-1 [35]. This possibility is supported by our observation that
the amount of IRS-1 phosphorylated on Tyr 896 is very high in
Hs 578T cells stimulated with IGF-1 and relatively high in HBL-
100 cells stimulated with IGF-1 (data not shown), which indicates
that strong induction of IRS-1 tyrosine phosphorylation in response
to IGF-1 in Hs 578T and HBL-100 cells may contribute to the re-
sponse of these cells to IGF-1. By contrast, serine phosphorylation of
IRS-1 attenuates IGF receptor signal transduction [50], and it is pos-
sible that differential serine phosphorylation of IRS-1 may influence
the responsiveness to IGF-1 of the different triple-negative breast
cancer cell lines. It seems that the responsiveness of individual cells
to IGFs results from the composite expression of different compo-
nents of the IGF signal transduction pathway and is not determined
solely on the basis of the level of expression of the IGF receptors.
The potential consequence of IGF receptor concentration in triple-
negative breast cancer cells on their biologic responsiveness to IGFs
was investigated further by measuring phosphorylation of IGF recep-
tors, Akt and MAPK, growth stimulation, and protection from induc-
tion of cell death effected by different concentrations of IGF-1 in cells
that express high and low receptor concentrations. Our results show
that, whereas the concentration dependence of the induction of IGF
receptor phosphorylation is similar regardless of the number of recep-
tors present in the cells, the concentration of IGF-1 required to elicit
biologic responses was higher in cells that express lower receptor levels.
These observations may have therapeutic implications because they
suggest that a higher dose of an IGF-1 antagonist would be required
to inhibit tumor cells with high receptor levels. A threshold level of
phosphorylated receptor may be required to elicit a biologic response,
and this threshold is achieved at lower IGF-1 concentrations in cells
that contain high receptor levels than in cells that contain low receptor
levels. Importantly, however, even cells that express small amounts of
IGF receptors are protected from cell death, and their proliferation in-
creased in the presence of relatively low IGF-1 concentrations.
There is a dearth of treatment options for triple-negative breast can-
cers because their phenotype renders them unresponsive to hormonal
or HER2-targeted therapies [1,2,48]. To date, the emphasis has been
on cytotoxic agents. They respond better than other types of breast can-
cer to neoadjuvant chemotherapy, but patients with residual disease
tend to relapse and die earlier. Other therapeutic targets are being eval-
uated in triple-negative breast cancer. High levels of EGFR are ex-
pressed in triple-negative tumors. Current data suggest, however, that
most triple-negative cancers respond transiently, if at all, to EGFR in-
hibition. Trials of vascular endothelial growth factor, Src, MEK, PARP,
and histone deacetylase inhibitors have been initiated. These studies
reflect current endeavor to provide a solution to the large clinical chal-
lenges presented by triple-negative breast cancers.
Although the IGF signal transduction pathway has attracted con-
siderable interest as a therapeutic target for the treatment of cancer
[17,52], current trials of IGF signal transduction pathway inhibitors
in breast cancer are in combination with existing agents on hormone
responsive or HER2-positive cancers. IGF inhibitors are not being
tested on triple-negative breast cancers because there have been in-
sufficient data from preclinical models to indicate that triple-negative
breast cancer cells are IGF-responsive.
The present study demonstrates that not only are the receptors
and downstream signal transduction proteins present and phosphor-
ylated in response to IGF-1 but that triple-negative breast cancer cell
proliferation and survival, two key hallmarks of a cancer cell, are
stimulated by IGF-1. Some of the cell line models in this study were
established from young (HBL-100, MDA-MB-435s, MDA-MB-
468, MDA-MB-231) and black (MDA-MB-468) women who are
more likely to develop triple-negative breast cancer. In addition,
the cell lines were established from primary tumors and metastatic
cells. Our results suggest, therefore, that therapies targeted against
the IGF signal transduction pathway could provide part of the arsenal
to fight triple-negative breast cancer and could be used for the treat-
ment of residual primary and systemic disease.
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